

Louisiana Revised Statutes of 1950

Title 40 – Public Health and Safety

Chapter 12 – Health Care Cost Control

[Editor’s Note: This new part was created by Act 220 of the 2017 Legislature, effective August 1, 2017. Subsequent amendments are noted herein.]

Part VIII. Pharmaceutical Cost Transparency

Subpart A. General Provisions

§2255.1. Definitions

As used in this Part, the following words have the following meanings unless the context indicates otherwise:

- (1) “Prescription drug” means a drug as defined in [21 U.S.C 321](#).
- (2) “Prescription drug marketing” means to provide educational or marketing information or materials regarding a prescription drug in any form including but not limited to all of the following:
 - (a) Face-to-face meetings.
 - (b) Physical mailings.
 - (c) Telephone conversations.
 - (d) Electronic mail or facsimile.

Subpart B. Disclosure of Prescription Drug Price Information

§2255.11. Disclosure of prescription drug price information

Each drug manufacturer or pharmaceutical marketer who engages in any form of prescription drug marketing to a prescriber, his designee, or any member of his staff in Louisiana shall provide to the Louisiana Board of Pharmacy no later than January first, April first, July first, and October first of each calendar year the current wholesale acquisition cost information for the United States Food and Drug Administration approved drugs marketed in the state by that manufacturer.

(end of Part VIII of Chapter 12)

(end of Chapter 12)